Syndax Pharmaceuticals (SNDX) Income towards Parent Company: 2015-2020
Historic Income towards Parent Company for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Dec 2020 value amounting to -$19.9 million.
- Syndax Pharmaceuticals' Income towards Parent Company fell 39.81% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 24.13%. This contributed to the annual value of -$318.5 million for FY2024, which is 52.40% down from last year.
- As of Q4 2020, Syndax Pharmaceuticals' Income towards Parent Company stood at -$19.9 million, which was down 0.04% from -$19.9 million recorded in Q3 2020.
- Over the past 5 years, Syndax Pharmaceuticals' Income towards Parent Company peaked at -$8.4 million during Q2 2016, and registered a low of -$19.9 million during Q4 2020.
- Its 3-year average for Income towards Parent Company is -$17.1 million, with a median of -$17.2 million in 2018.
- Per our database at Business Quant, Syndax Pharmaceuticals' Income towards Parent Company crashed by 145.93% in 2016 and then grew by 26.52% in 2019.
- Syndax Pharmaceuticals' Income towards Parent Company (Quarterly) stood at -$10.9 million in 2016, then crashed by 74.99% to -$19.0 million in 2017, then dropped by 1.61% to -$19.3 million in 2018, then climbed by 26.52% to -$14.2 million in 2019, then tumbled by 39.81% to -$19.9 million in 2020.
- Its Income towards Parent Company stands at -$19.9 million for Q4 2020, versus -$19.9 million for Q3 2020 and -$16.6 million for Q2 2020.